Chronic liver injury and inflammation triggered by metabolic abnormalities initiate the activation of hepatic stellate cells (HSCs), driving fibrosis and parenchymal dysfunction, culminating in disorders such as nonalcoholic steatohepatitis (NASH). Unfortunately, there are currently no approved drugs capable of effectively treating NASH due to the challenges in addressing fibrosis and restoring extracellular matrix (ECM) homeostasis. We discovered a significant up-regulation of interleukin-11 (IL-11) in fibrotic livers using two well-established murine models of NASH. To leverage this signaling pathway, we developed a nanoparticle (NP)-assisted RNA interfering approach that specifically targets activated HSCs (aHSCs), blocking IL-11/ERK signaling to regulate HSC transdifferentiation along with fibrotic remodeling. The most potent NP, designated NP-AEAA, showed enhanced accumulation in fibrotic livers with NASH and was primarily enriched in aHSCs. We further investigated the therapeutic efficacy of aHSC-targeting NP-AEAA encapsulating small interfering RNA (siRNA) against IL11 or its cognate receptor IL11ra1 (termed siIL11@NP-AEAA or siIL11ra1@NP-AEAA, respectively) for resolving fibrosis and NASH. Our results demonstrate that both siIL11@NP-AEAA and siIL11ra1@NP-AEAA effectively inhibit HSC activation and resolve fibrosis in two well-established murine models of NASH. Notably, siIL11ra1@NP-AEAA exhibits a superior therapeutic effect over siIL11@NP-AEAA, in terms of reducing liver steatosis and fibrosis as well as recovering liver function. These results constitute a targeted nanoparticulate siRNA therapeutic approach against the IL-11 signaling pathway of aHSCs in the fibrotic liver, offering a promising therapeutic intervention for NASH and other diseases.

KEYWORDS: activated HSC-targeted nanoparticles, targeted delivery of RNA-based therapeutics, nonalcoholic steatohepatitis, liver fibrosis, IL-11 signaling

INTRODUCTION

With the rising prevalence of metabolic disorders such as obesity and diabetes, nonalcoholic steatohepatitis (NASH) is becoming a global public health crisis affecting approximately 5% of individuals worldwide.1−3 NASH is characterized by hepatic lipid accumulation and inflammation, typically accompanied by pericellular fibrosis.4−6 Progressive liver fibrosis in NASH is the main predictor of liver-related mortality,7 and the clinical focus for NASH therapies has recently shifted towards mitigating fibrosis as a primary outcome measure.8,9 It is widely accepted that the fibrogenic transformation of fibroblasts into myofibroblasts represents a key step in NASH pathogenesis.10−12 This fibroblast-to-myofibroblast transformation is caused by the activation of hepatic stellate cells (HSCs).13−15 The underlying mechanisms of HSC activation have been studied to inhibit the profibrogenic signaling in activated HSCs (aHSCs) to combat NASH and related fibrotic diseases, however, achieving therapeutic strategies with enhanced specificity and efficacy has perplexed researchers for many years, and currently there are no effective drugs approved for the treatment of liver fibrosis.16−19
Recent studies have confirmed that interleukin-11 (IL-11) is a vital profibrotic cytokine downstream of multiple stimuli that are involved in myofibroblast transdifferentiation and organ fibrosis. Excess secreted IL-11 in NASH liver can bind with its cognate receptor (IL11ra1) and glycoprotein 130 (gp130) complex, driving HSC activation and noncanonical extracellular signal-regulated kinase (ERK)-dependent autocrine signaling responsible for pro-inflammatory and fibrogenic protein synthesis and subsequently, NASH progression. Using both high-fat, high-cholesterol, methionine- and choline-deficient diet (HFCMCD)- and high-fat/high-cholesterol diet (HFHC)- induced murine models of NASH, we discovered a significant up-regulation of IL-11 and actin alpha 2, smooth muscle (ACTA2) in fibrotic livers (Figure S1A−C and Figure S2A−C). The strong correlation between IL-11 expression and ACTA2, which is a hallmark of HSC activation, was identified by quantitative analysis of immunohistochemistry images (Figure S1D and Figure S2D), which is consistent with previous reports. Western blotting also indicated that the increased expression of IL-11 and IL11ra1 in HSCs derived from both murine NASH models was closely associated with the activation of HSCs and elevated levels of ACTA2 (Figure S1E,F and Figure S2E,F), revealing the prominent roles IL-11 and IL11ra1 play in the pathogenesis of NASH. We therefore hypothesize that inhibiting IL-11 signaling by down-regulation...
of IL-11 or IL11ra1 in aHSCs can provide therapeutic benefits for NASH and related fibrosis.

RNA interference (RNAi) has emerged as a robust strategy for the treatment of many diseases. To date, the majority of FDA-approved small interfering RNA (siRNA) therapeutics exclusively deliver siRNAs to parenchymal hepatocytes using an N-acetylgalactosamine (GalNAc)-based targeting strategy. NP platforms that allow the specific delivery of therapeutic
siRNA to aHSCs for the treatment of NASH and related fibrosis have yet to be explored. Thus, there is an unmet demand to develop delivery vehicles capable of specifically transferring siRNA to cells other than liver hepatocytes to fully harness the potential of siRNA-based therapy for the treatment of liver diseases.

Herein, we present a targeted nanoparticle-mediated RNA therapeutic approach for the treatment of NASH and NASH-related liver fibrosis. Specifically, we demonstrate a proof-of-concept for the design and preclinical use of an aHSC-targeting NP-RNA interference approach against IL-11 signaling for the inhibition of hepatic fibrosis and amelioration of NASH (Figure 1). Our targeted nanoparticle therapeutics are composed of three components: (i) a cationic lipid-like molecule designated G0-C14 which facilitates siRNA entrapment and endosome escape following cellular internalization;25 (ii) a biodegradable poly(lactide-co-glycolide)-b-poly(ethylene glycol) (PLGA-PEG) acting as a matrix protecting the encapsulated siRNA and prolonging the NP plasma circulation time; and (iii) a small molecule as targeting ligand to liver aHSCs (Figure 2A). Specifically, we chemically linked either vitamin A (VA), which specifically recognizes the retinol-binding protein (RBP) receptor, or aminoethyl anisamide (AEAA), which specifically recognizes the sigma-1 receptor (Sig-1R), at the free PEG end of PLGA-PEG to develop two different aHSC-targeting NPs. Using an HFCMCd-induced murine model of NASH, we showed that the NP designated NP-AEAA maximized accumulation in fibrotic NASH livers and was primarily enriched in aHSCs. We further investigated the efficacy of an aHSC-targeting NP-AEAA encapsulating siRNA against either IL11 or IL11ra1 (termed siIL11@NP-AEAA or siIL11ra1@NP-AEAA, respectively) for ameliorating NASH and related hepatic fibrosis in both HFCMCD- and HFHC-induced murine models of NASH. Our results demonstrate that both siIL11@NP-AEAA and siIL11ra1@NP-AEAA effectively inhibit HSC activation and resolve fibrosis and inflammation by blocking the noncanonical IL-11/ERK signaling in the two well-established preclinical NASH models. siIL11ra1@NP-AEAA exhibits a superior therapeutic effect in terms of reducing liver steatosis and fibrosis, as well as recovering liver function when compared with siIL11@NP-AEAA. This work presents a targeting NP platform capable of delivering siRNA against IL-11 signaling to aHSCs, offering a promising therapeutic strategy for NASH patients suffering from fibrosis. Additionally, the developed NP-aided aHSC-targeting RNA therapeutic approach provides insights into the treatment of many other hepatic diseases.

RESULTS

Design, Synthesis, and Characterization of siRNA-Loaded NPs for aHSC-Specific Targeting. It has been reported that the liver usually captures up to 90% of administered NPs from blood circulation due to its biological filtration function.28 This intrinsic characteristic can be leveraged to endow NPs with the capability to target hepatic diseases. However, most of the captured NPs are preferentially taken up and sequestered by liver-resident Kupffer cells, followed by elimination through the hepatobiliary system,29 resulting in limited NP delivery to the targeted diseased cells. Developing delivery strategies capable of specifically transferring nucleic acid-based therapeutics to certain types of liver cells is critically needed to enable the use of NPs for treating hepatic diseases. Using a microfluidic method, we fabricated engineered NPs through self-assembly of G0-C14 together with targeting polymeric excipients for selective delivery of RNA into nonparenchymal aHSCs in the fibrotic liver. G0-C14 was synthesized by reacting poly(amideamine) (PAMAM) dendrimer generation 0 with 1,2-epoxytetradecane as described in Figure S3. The chemical structure of G0-C14 was characterized by 1H nuclear magnetic resonance (1H NMR, 400 MHz, Chloroform-d) as shown in Figure S4. To facilitate the active transport of siRNA-loaded NPs to aHSCs, we synthesized VA- and AEAA-functionalized PLGA-PEG as two different targeting polymeric excipients. VA in blood circulation can be specifically taken up by HSCs via RBP receptors.30 This intrinsic attribute makes VA an attractive ligand for achieving the selective delivery of a drug to HSCs. AEAA is a benzamide-based compound that has a high affinity for the Sig-1R overexpressed on aHSCs in the metastatic liver.31 We synthesized PLGA-PEG-VA by coupling VA to the carboxy end-group of PLGA-PEG-COOH as shown in Figures S5 and S6. We measured the UV absorbance at 328 nm as an indicator of the chemical composition of VA in the PLGA-PEG-VA conjugate. The amount of VA attached to the polymer conjugate was calculated as 0.62% w/w, corresponding to 0.95 molar VA per molar of PLGA-PEG-VA. Figure S7 demonstrates the synthetic route we used to synthesize PLGA-PEG-AEAA. 1H NMR characteristic signals of aryl of AEAA (7.40 and 7.16 ppm) and methine of PLGA (5.28–5.05 ppm) were used to determine the chemical composition of AEAA in PLGA-PEG-AEAA. The result revealed that 0.97 molar AEAA was covalently attached to per molar of the polymer conjugate.

The siRNA complexation ability of G0-C14 was determined by an agarose gel electrophoresis assay. As shown in Figure 2B, siRNA could be successfully retarded by G0-C14 at a siRNA/G0-C14 weight ratio of 1:20. This ratio was chosen to form siRNA-loaded NPs in the following studies. We then formulated siRNA-loaded NPs with different weight ratios of PLGA-PEG-VA or PLGA-PEG-AEAA (2.5%, 5%, and 10% w/w the total polymeric excipients) and evaluated their key physicochemical attributes. No notable changes in particle size were observed for NPs prepared with 2.5% and 5% w/w of targeting polymeric excipients, while particle size slightly increased from 82.80 ± 2.09 nm (siRNA@NP-VA) to 91.25 ± 2.27 nm (siRNA@NP-VA10%) and 88.33 ± 1.71 nm (siRNA@NP-AEAA10%) when 10% w/w PLGA-PEG-VA was replaced with targeting polymeric excipients (Figure 2C). All NPs showed similar zeta potential in PBS solution (pH = 7.4) and siRNA encapsulation efficiency (EE) of around 93% (Figure 2D,E and Table S1).

Primary HSCs isolated from C57BL/6J mice were stimulated with transforming growth factor-β1 (TGF-β1) to induce their transformation into aHSCs, with the percentage of ACTA2-positive (ACTA2+ cells surpassing 98%. Cellular internalization of different Cy5.5-labeled NPs (Cy5.5-NPs) was evaluated in the cultured aHSCs. Flow cytometry analysis exhibited that NP uptake by aHSCs increased with an increase in the weight ratio of the incorporated targeting moiety and reached a plateau when NPs were formulated with the PLGA-PEG-ligand at a weight ratio of 5% or above (Figure 2F,G). We noted that aHSCs treated with siRNA@NP-AEAA showed the highest Cy5.5 fluorescence intensity, which was 1.89-fold higher than that of siRNA@NP-VA and 6.05-fold higher than that of siRNA@Cy5.5-NP. Confocal laser scanning microscopy (CLSM) images of Cy5.5-NP-AEAA loaded with FAM-labeled siRNA (termed siRNA@[Cy5.5-NP-AEAA])
further confirmed that incorporation of 5% w/w AEAA resulted in more siRNA and NPs colocalized within aHSCs (Figure 2H). Notably, cellular uptake of FAM-siRNA@Cy5.5-NP-AEAA by aHSCs was substantially inhibited in the presence of

Figure 3. NP-AEAA characterization and in vivo biodistribution. (A) Representative TEM images of siRNA@NP and siRNA@NP-AEAA. Scale bars represent 50 nm. (B) Stability of free siRNA and NP-AEAA-encapsulating siRNA against serum at various time points. (C) The size and PDI of siRNA@NP-AEAA were monitored by dynamic light scattering (DLS) for 72 h (n = 3). (D–F) CCK8 assay of siRNA@NP and siRNA@NP-AEAA in HSC-T6 (D), 3T3 (E) and primary hepatocytes (F) (n = 5). (G) IVIS imaging of heart (He), liver (Li), spleen (Sp), lung (Lu), and kidneys (Ki) collected at 24 h from HFCMCD-fed mice following intravenous injection with indicated NPs. (H) Quantification analysis of the Cy5.5 fluorescence signal in HFCMCD mouse livers by Living Image 4.5 software (n = 3). (I) Immunofluorescence analysis of the colocalization of Cy5.5-labeled NPs (red) and ACTA2+ aHSCs (green, Cora594-labeled) in liver sections from HFCMCD-induced fibrotic mice. Scale bars are 100 μm. White arrowheads indicate the colocalization of NPs with ACTA2. (J) Impact of targeting ligands on in vivo cellular uptake of Cy5.5-labeled (RF+) NPs by ACTA2+ aHSCs. Three mice were measured for each group, and two randomly selected liver sections of each mouse were analyzed by ImageJ, resulting in a total of six measurements. (K) Intracellular distribution of NPs in fibrotic liver sections from HFCMCD mice receiving siRNA@Cy5.5-NP or siRNA@Cy5.5-NP-AEAA. The fluorescence intensity profiles were measured along the yellow line drawn across representative areas. Sig-1R was visualized by Cora594 (green), and NPs were labeled with Cy5.5 (red). Scale bars represent 100 μm. Statistical significance was determined via a one-way ANOVA with post hoc Tukey test (H, J). Results are presented as means ± SD. **P < 0.01, ***P < 0.001, ****P < 0.0001.
the Sig-1R antibody, which is likely a result of the blockade of Sig-1R (Figure 2H). Flow cytometry analysis shows similar results (Figure 2I). Compared with nontargeted FAM-siRNA@Cy5.5-NP, FAM-siRNA@Cy5.5-NP-AEAA treatment resulted in a significantly higher percentage of aHSCs positively stained with both FAM and Cy5.5; this percentage markedly decreased from 80.6% to 56.3% when cells were pretreated with Sig-1R antibody, thus indicating Sig-1R-mediated endocytosis. It is noteworthy that the enhancement in NP uptake observed in NP-AEAA-treated aHSCs was not observed in quiescent HSCs (qHSCs) that do not express Sig-1R (Figure 2K and Figure 5B). FAM fluorescence intensity in aHSCs treated with FAM-siRNA@NP-AEAA was 2.18-fold higher than that in qHSCs treated with the same targeted NPs (Figure 2K). As expected, the enhanced fluorescence intensity observed in FAM-siRNA@NP-AEAA-treated aHSCs was dramatically reduced by Sig-1R antibody treatment, indicating that the aHSC-specific uptake of NP-AEAA is mainly mediated via the AEAA-Sig-1R interaction.

**siRNA@NP-AEAA Characterization and In Vivo Targeting Evaluation.** We characterized the morphologies of siRNA@NP and siRNA@NP-AEAA using transmission electron microscopy (TEM). As shown in Figure 3A, both NPs showed a spherical and uniform structure, revealing that the incorporation of targeting moieties has no obvious effect on NP morphology. We then performed gel electrophoresis to examine whether the developed NP-AEAA could protect siRNA from serum nuclease degradation. Figure 3B shows that naked siRNA was rapidly degraded in PBS supplemented with 20% fetal bovine serum (FBS), while siRNA extracted from NP-AEAA remained intact after 24 h of incubation, indicating an increase in stability of NP-formulated siRNA. Additionally, no significant change in NP size or polydispersity index (PDI) was observed after 72 h of incubation of siRNA@NP-AEAA with PBS (pH = 7.4) containing 20% FBS at 37 °C (Figure 3C). Cytotoxicity of siRNA@NP and siRNA@NP-AEAA was assessed in the rat liver stellate cell line HSC-T6, mouse fibroblast cell line NIH/3T3, and mouse primary hepatocytes using cell counting kit-8 (CCK8) assay. The results showed no cytotoxicity in the range of tested concentrations, and the viability of the three cells remained above 90% at a high NP concentration up to 500 μg/mL (Figure 3D–F).

The superior targeting efficacy of NP-AEAA in vitro prompted us to investigate whether NP-AEAA could be specifically delivered to aHSCs in HFCMCD-induced fibrotic mice. C57BL/6j mice were fed the HFCMCD diet for 12 weeks to induce hepatic lesion characteristics of NASH, with steatosis, lobular inflammation, and severe fibrosis (Figure S10). An IVIS imaging system was used to examine the biodistribution of different NPs in vivo following intravenous injection. As shown in Figure 3G,H, intravenously injected siRNA@Cy5.5-NP-VA56 and siRNA@Cy5.5-NP-AEAA56 exhibited greater accumulation in fibrotic livers compared with nontargeted siRNA@Cy5.5-NP, and siRNA@Cy5.5-NP-AEAA resulted in the highest Cy5.5 fluorescence intensity in liver tissues. It is expected to observe NP accumulation in the liver and spleen due to the sinusoidal endothelial capillaries in the liver and a large population of macrophages in the spleen.32,33 As the kidney is the major organ responsible for drug elimination, NP accumulation is also expected in this organ (Figure S11).30 Immunofluorescence staining of liver sections indicated that Cy5.5-NP-AEAA primarily colocalized within aHSCs positively stained for ACTA2 (the most reliable aHSC marker), generating bright yellow signals (Figure 3I). The quantitative analysis of imaging illustrated that the percentage of Cy5.5 red fluorescence-positive (RF+) cells accounted for 32.9 ± 2.9% of the total area of ACTA2+ aHSCs in liver sections obtained from mice receiving Cy5.5-NP-AEAA, which was higher than those of Cy5.5-NP-VA (18.1 ± 1.7%) and nontargeted Cy5.5-NP treatment groups (11.5 ± 0.8%) (Figure 3J). Intriguingly, Cy5.5-NP-AEAA-mediated enhanced NP accumulation in fibrotic livers of HFCMCD mice was not observed in healthy mouse livers, where ACTA2+ aHSCs were hardly detected (Figures S12 and S13). This is presumably due to the limited uptake of NP-AEAA by qHSCs in the livers of normal chow-fed healthy mice. Consistent with in vitro results, the in vivo results further demonstrate that incorporation of AEAA facilitates NP accumulation within fibrotic livers more efficiently than VA, and injected NP-AEAA is preferentially localized within aHSCs.

To validate the HSC-specific targeting ability of NP-AEAA, we collected hepatocytes and HSCs from HFCMCD mice receiving treatment of siRNA@Cy5.5-NP or siRNA@Cy5.5-NP-AEAA and conducted flow cytometry analysis. The results showed that the targeted siRNA@Cy5.5-NP-AEAA achieved 8.5-fold higher percentage of Cy5.5-positive (Cy5.5+) HSCs compared with its nontargeted counterpart siRNA@Cy5.5-NP, but both NPs showed similar delivery to parenchymal hepatocytes (Figure S14A–C). The ratio of Cy5.5+ cells between HSCs and hepatocytes (Cy5.5+ HSCs/Cy5.5+ hepatocytes, an indicator of HSC selectivity) was calculated to be 1.73 for siRNA@Cy5.5-NP-AEAA, with 41.5% of the total HSCs displaying Cy5.5+ positive cells and 24.0% hepatocytes colocalized with NPs (Figure S14C). In contrast, only a small ratio of 0.21 was observed for siRNA@Cy5.5-NP. It has been reported that HSCs are difficult to transfect and take up foreign materials in comparison with hepatocytes, a ratio of Cy5.5+ HSCs/Cy5.5+ hepatocytes below 1 is expected.35 Notably, our developed siRNA@Cy5.5-NP-AEAA achieves a 1.73-fold higher ratio, indicating the dramatically increased preferential uptake of NPs by HSCs over hepatocytes in vivo.

To investigate whether the in vivo uptake of NP-AEAA by aHSCs is mediated by Sig-1R, we examined the expression and colocalization of Sig-1R in liver tissues. Figure S15 showed markedly elevated expression of Sig-1R in the HFCMCD-induced fibrotic liver compared with the healthy control, and colocalization of Sig-1R with ACTA2 suggests that aHSCs express high levels of Sig-1R. Additionally, we observed robust expression of Sig-1R and strong Cy5.5 fluorescence signal of NPs in fibrotic livers of HFCMCD mice receiving siRNA@Cy5.5-NP-AEAA (Figure 3K). The line scanning profiles toward the selected cells demonstrated that the red Cy5.5 signal from NPs primarily overlapped with the green Sig-1R signal. In contrast, treatment with nontargeted siRNA@Cy5.5-NP resulted in much less NP accumulation in fibrotic liver sections as well as minimal colocalization of the red NP signal with the green Sig-1R. On the other hand, reduced Sig-1R expression was observed in liver sections obtained from healthy mice receiving NP-AEAA, leading to limited NP accumulation (Figure S16), which is consistent with the data shown in Figure S12. Taken together, these results reveal that homing of NP-AEAA to aHSCs is mediated by the interaction of AEAA and Sig-1R that is expressed on aHSCs.

**si11@NP-AEAA and si11tra1@NP-AEAA Both Inhibit HSC Activation, Migration, and Invasion through ERK Signaling Blockade.** We next studied the effect of IL-11.
Figure 4. Suppression of IL-11 or IL11RA1 using NP-AEAA siRNA therapeutics inhibits the activation, migration, and invasion of HSCs in vitro. (A) Representative images of ACTA2 and COL1A1 immunostaining in HSCs treated with TGF-β1 (20 ng/mL) for 48 h in the presence of PBS, siScr@NP-AEAA, siIL11@NP-AEAA, or siIL11ra1@NP-AEAA. HSCs treated with PBS and without any stimulation served as the “basal” state. Scale bars represent 50 μm. (B, C) Quantification analysis of ACTA2+ cells (B) and COL1A1 immunofluorescence intensity (C) in HSCs as shown in Figure 4A. n = 4. (D) Western blots of IL-11, IL11RA1, COL1A1, ACTA2, phosphorylation, and total expression of ERK in HSCs treated with PBS, siScr@NP-AEAA, siIL11@NP-AEAA, or siIL11ra1@NP-AEAA followed by TGF-β1 stimulation (20 ng/mL) for 48 h. n = 2 samples per group. GAPDH was used as a loading control to normalize protein levels, with HSCs treated with PBS alone serving as a negative control. MW, molecular weight. (E) Schematic illustration of the HSC migration and invasion assay using a two-compartment Boyden chamber system. Cells were incubated with PBS, siScr@NP-AEAA, siIL11@NP-AEAA, or siIL11ra1@NP-AEAA in the top chamber, and the medium in the bottom chamber was supplemented with chemotactic stimuli. For the invasion assay, the upper side of the polycarbonate membrane in the upper chamber was coated with a Matrigel matrix enriched with type IV collagen. HSCs migrate and invade through the membrane into the bottom chamber. (F, G) Microscopy images (F) and quantitative analysis (G) of stained HSCs that invaded through the Matrigel matrix and migrated from the top chamber to the bottom chamber in response to TGF-β1 stimulation (20 ng/mL) following the indicated treatments (n = 3). Images from two randomly selected fields per well were acquired, and three independent wells were measured, resulting in a total of six measurements. Migration (%) or invasion (%) was expressed as a percentage of NP-treated cells passing through the membrane relative to the number of PBS-treated cells that traversed the membrane following stimulation with TGF-β1. Scale bars represent 100 μm. Statistical significance was determined via a one-way ANOVA with Tukey test (B, C, and G). Results are presented as means ± SD. ****p < 0.0001, n.s., not significant, P > 0.05.
Figure 5. siIL11ra1@NP-AEAA shows superior efficacy on hepatic fibrosis and inflammation in an HFCMCD-induced NASH model. (A) Schematic diagram of the HFCMCD-induced NASH model and treatment timeline for saline, siScr@NP-AEAA, siIL11ra1@NP, siIL11@NP-AEAA, or siIL11ra1@NP-AEAA therapy. (B) Representative microscopic images of Masson’s trichrome staining (collagen fibers are stained blue; muscle tissue is stained red), Sirius red staining (collagen I and III fibers are red) and H&E staining (black arrows indicate macrovesicular steatosis) of liver tissue sections obtained from normal chow-fed healthy mice, or HFCMCD-fed mice treated with indicated NPs. Scale bars represent 100 μm. (C) Quantification analysis of aniline blue- and Sirius red-positive areas in liver sections. n = 6 mice per group. (D) Serum ALT and AST levels of mice receiving the indicated treatments. n = 6 mice per group. (E, F) Hepatic mRNA expression of profibrogenic (Acta2, Col1α1) (E) and proinflammatory (Ccl2, Ccl5) genes (F) following indicated treatments. n = 6 mice per group. (G) Relative mRNA expression of Timp1/Mmp2 in livers of HFCMCD mice receiving the indicated treatments. n = 6 mice per group. (H) Quantification analysis of liver hydroxyproline content. n = 6 mice per group. (I) Western blots of IL-11, IL11RA1, COL1A1, ACTA2, phosphorylation, and total expression of ERK in the livers collected from the indicated groups. n = 2 mice per group. GAPDH was used as a loading control to normalize the protein levels. Statistical significance was determined via a one-way ANOVA with a post hoc Tukey test (C–H). Results are presented as means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s., not significant, P > 0.05.
stimulation with NASH stimuli, including TGF-β1, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF) and oxidative stress (H_{2}O_{2}), led to IL-11 secretion from primary HSCs and a marked increase in the proportion of ACTA2^+ cells (Figure S17). These findings imply that IL-11 is a downstream effector of multiple NASH stimuli and is responsible for the HSC-to-myofibroblast transformation. We then treated TGF-β1-stimulated HSCs with siIL11- or siIL11ra1-encapsulated NP-AEAA (termed siIL11@NP-AEAA or siIL11ra1@NP-AEAA, respectively). Immunofluorescence staining revealed that both treatments effectively inhibited the elevated expression of ACTA2 and collagen type I alpha 1 (COL1A1, the main components of the ECM) induced by TGF-β1 and other stimulation factors, such as bFGF, PDGF and H_{2}O_{2} (Figure 4A–C and Figure S18). Western blotting results further confirmed a reduction in the expression of IL-11 and IL11RA1 upon treating TGF-β1-stimulated HSCs with siIL11@NP-AEAA and siIL11ra1@NP-AEAA, respectively, resulting in a noticeable decrease in the level of TGF-β1-induced expression of ACTA2 and COL1A1 (Figure 4D and Figure S19). It is believed that IL-11-driven canonical ERK phosphorylation is associated with HSC activation and NASH pathologies.37 Figure 4D and Figure S19 show that treatment with siIL11@NP-AEAA or siIL11ra1@NP-AEAA abolished TGF-β1-induced phosphorylated ERK (p-ERK) expression in HSCs, suggesting that the developed siRNA therapeutics effectively inhibit HSC activation and ECM production by blocking IL-11-dependent ERK signaling.

The basement membrane-like matrix present within the space of Disse provides a residential microenvironment for HSCs.36 During liver fibrosis and NASH pathologies, this basement membrane-like matrix gradually transitions to a fibrillar matrix and is accompanied by the release of profibrogenic growth factors such as TGF-β1 from aHSCs, inflammatory cells, and hepatocytes.37,38 Stimulation with profibrogenic growth factors further activates HSCs, prompting them to invade adjacent areas and migrate toward injured areas of the Disse space, thus contributing to the spread and progression of the disease.39 Here we examined the effect of siIL11@NP-AEAA and siIL11ra1@NP-AEAA on the stimulated migration of HSCs via a classical two-compartment Boyden chamber system. Figure 4E presents a schematic illustration of the experimental design. Cells were incubated on the upper side of the polycarbonate membrane in the upper chamber, simulating the ECM and providing an anchor for resident HSCs. Similarly, treatments with siIL11@NP-AEAA and siIL11ra1@NP-AEAA significantly reduced the invasion rate of TGF-β1-stimulated HSCs to 15.3% and 13.52%, respectively, compared to siScr@NP-AEAA and PBS controls (Figure 4F,G). These data reveal the pivotal role of IL-11 in HSC migration and invasion and suggest that effective suppression of IL-11 or IL11ra1 through NP-AEAA-assisted siRNA therapeutics could anchor HSCs and prevent them from dispersing in the Disse space and from migrating to sites of injury in the liver, thereby inhibiting the progression of liver fibrosis.

**siIL11ra1@NP-AEAA Ameliorates Fibrosis and Inflammation in an HFCMCD-Induced NASH Model.** In preliminary studies, we investigated the antibifibrotic effect of siIL11ra1@NP-AEAA at a high dose (0.6 mg/kg of siIL11ra1) and a low dose (0.3 mg/kg of siIL11ra1) in an HFCMCD-induced NASH model (Figure S20A). The results showed that treatments with both high and low doses of siIL11ra1 decreased the liver damage markers of ALT and AST, with a high dose of siIL11ra1@NP-AEAA treatment having a more pronounced effect than low dose treatment (Figure S20B,C). HFCMCD mice receiving siIL11ra1@NP-AEAA treatment at a high dose showed substantially reduced hydroxyproline content in liver homogenates and Sirius red-stained fibrotic area in liver tissues compared with the low-dose treatment (Figure S20D–F). Additionally, we tested the silencing activity of siIL11ra1@NP-AEAA at different doses in HSCs isolated from HFCMCD-induced mice. Western blotting results showed that there was a dose-dependent silencing activity of siIL11ra1@NP-AEAA and ~63.7% knockdown of IL11RA1 could be achieved at a dose of 0.6 mg/kg (Figure S20G,H), indicating a positive correlation between antifibrotic effects and down-regulation of IL11RA1 in HSCs. Taken together, we selected a dose of 0.6 mg siRNA per kg for the following in vivo experiments. Figure 5A illustrates the therapeutic efficacy of aHSC-homing siRNA therapeutics that target the IL-11 signaling in the HFCMCD-induced NASH model. Masson’s trichrome and Sirius red staining, followed by quantitative analysis, revealed that the fibrotic regions were markedly increased in the livers of HFCMCD mice treated with saline or siScr@NP-AEAA in comparison with those of normal chow-fed healthy mice (Figure 5B,C). NP-mediated silencing of IL-11 or IL11ra1 decreased the aniline blue- or Sirius red-positive area in liver tissues, with targeted NP-AEAA-mediated siRNA therapeutics having a more pronounced effect than non-targeted NP. Specifically, HFCMCD mice receiving siIL11ra1@NP-AEAA treatment demonstrated the fewest fibrotic regions among groups (Figure 5B,C). Serological analysis revealed that the HFCMCD diet induced a significant liver injury, as evidenced by increased serum levels of alanine transaminase (ALT) and aspartate transaminase (AST). Although nontargeted siIL11ra1@NP treatment mitigated liver damage compared with HFCMCD controls, targeted siIL11ra1@NP-AEAA treatment reduced both enzymes to near normal ranges (Figure 5D).

Differentiation of HSCs into myofibroblast-like aHSCs is a key step involved in the progression of NASH and fibrosis, which leads to elevated expression of ACTA2 and promotes the production of COL1A1 and proinflammatory chemokines C–C motif chemokine ligands 2 (CCL2) and CCL5.40,41 Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of liver homogenates indicated that blockage of the IL-11 signaling pathway mediated by NPs markedly down-regulated the elevated expression levels of Acta2, Col1a1, Ccl2, and Cd5 induced by the HFCMCD diet. Among the test
groups, NP-AEAA-mediated specific transfer of siRNA targeting IL11ra1 to aHSCs showed the highest efficacy in inhibiting the expression of proinflammatory and profibrogenic genes (Figure 5E,F). In fibrotic livers, aHSCs are the primary source of tissue inhibitors of metalloproteinase 1 (TIMP1) production. The balance of TIMP1 and matrix metalloproteinase 2 (MMP2) expression was disrupted in livers of HFCMCD mice with increased Timp1/Mmp2 ratio (Figure 5G), indicating an abnormal ECM accumulation. Treatment with siIL11ra1@NP-AEAA in vivo restored the ratio to the similar levels seen in normal chow-fed healthy mice, while both siIL11ra1@NP and siIL11@NP-AEAA had a reduced antifibrotic effect in comparison (Figure 5G). The level of hydroxyproline, a major component of fibrillar collagen, was found to be the lowest in HFCMCD mice receiving siIL11ra1@NP-AEAA, decreasing from 625 μg/g (siScr@NP-AEAA) to 348 μg/g in wet liver tissues (Figure 5H).

Western blotting analysis of liver homogenates demonstrated that the elevated expression of IL-11 and IL11RA1 in livers of HFCMCD mice was effectively diminished following treatment with siIL11@NP-AEAA and siIL11ra1@NP-AEAA. This was accompanied by a substantial reduction in the expression of ACTA2 and COL1A1 (Figure S1 and Figure S21). Consistent with the Western blotting results observed in
vitro (Figure 4D), both treatments were shown to inhibit pathological ERK activation in NASH livers, with \textit{siIL11ra1@NP-AEAA} exhibiting the lowest expression levels of \textit{ACTA2}, \textit{COL1A1}, and p-ERK (Figure 5I and Figure S21). To further validate HSC-specific silence activity of NP-AEAA, we also conducted Western blotting experiments to study NP-mediated down-regulation of \textit{IL-11} or \textit{IL11RA1} in HSCs isolated from HFCMCD-fed mice with liver fibrosis. The results showed that the targeted \textit{siIL11@NP-AEAA} significantly reduced \textit{IL-11} expression level to 38.7% in HSCs compared with saline and \textit{siScr@NP-AEAA} controls, but the nontargeted \textit{siIL11@NP} treatment did not (Figure S22A,B). Similarly, treatment with \textit{siIL11ra1@NP-AEAA} in vivo resulted in the lowest \textit{IL11RA1} expression in HSCs, which was decreased by 72.7%, 70.7%, and 74.4% compared with saline, \textit{siScr@NP-AEAA}, and \textit{siIL11ra1@NP}, respectively (Figure S22C,D). These results imply that NP-AEAA-formulated siRNA targeting \textit{IL-11} signaling in aHSCs effectively suppress HSC activation, inflammation, and ECM deposition in an HFCMCD-induced NASH model. \textit{siIL11ra1@NP-AEAA} exhibits a superior effect over \textit{siIL11@NP-AEAA}, probably due to its more potent inhibition of \textit{IL-11}-dependent ERK activation.

\textbf{Model.} Feeding with an HFC diet elicits profound hepatic steatosis, ballooning, inflammation, and fibrosis (Figure S23), which mirrors the pathogenesis of human NASH and thus was used as another clinically relevant model for in vivo efficacy evaluation.\textsuperscript{14} The NP treatment scheme for HFC-induced model mice is depicted in Figure 6A. Histopathological analysis of liver sections showed increased fibrotic regions along with micro- and macrovesicular lipid deposition in HFC mice receiving saline or \textit{siScr@NP-AEAA} treatment compared with the healthy controls (Figure 6B–H). All these hepatic lesion characteristics were attenuated in mice treated with nontargeted NP- or targeted NP-AEAA-formulated siRNA therapeutics. Relative to nontargeted \textit{siIL11ra1@NP}, both targeted \textit{siIL11@NP-AEAA} and \textit{siIL11ra1@NP-AEAA} treatments substantially reduced the aniline blue- or Sirius red-stained fibrotic area, micro- and macrovesicular steatosis, as well as Oil red O-stained lipid droplets in liver tissues, with the best therapeutic efficacy achieved by \textit{siIL11ra1@NP-AEAA} (Figure 6B–H). Similar to the Oil red O staining results, \textit{siIL11ra1@NP-AEAA} treatment most effectively decreased the liver triglyceride content in HFC mice among all the test groups (Figure 6I).

HFC mice receiving saline or \textit{siScr@NP-AEAA} treatment were characterized with elevated serum ALT and AST levels, enhanced expression of profibrogenic (\textit{Acta2}, \textit{Col1a1}) and...
proinflammatory (Ccl2, Ccl5) genes, as well as increased Timp1/Mmp2 ratio, and hydroxyproline content in liver homogenates, all of which were ameliorated in animals receiving NP- or NP-AEAA-formulated siRNA therapeutics (Figure 7A–E). In particular, siIL11ra1@NP-AEAA therapy reversed the liver damage biomarkers of ALT and AST, and fibrogenesis-associated Timp1/Mmp2 ratio to normal levels (Figure 7A,D), indicative of liver function recovery and favorable ECM remodeling.

Consistent with the HFCMCD-induced NASH model, Western blotting results showed that the upregulation of IL-11 and IL11RA1 in livers of HFHC mice was effectively suppressed after siIL11@NP-AEAA and siIL11ra1@NP-AEAA treatment along with a reduction in the expression of ACTA2, COL1A1, and p-ERK (Figure 7F). Similarly, HFHC mice treated with siIL11ra1@NP-AEAA exhibited the lowest expression levels of ACTA2, COL1A1, and p-ERK in the liver (Figure 7F). These results reveal that NP-AEAA-aided siRNA therapeutics against IL-11 signaling in aHSCs...
effectively inhibit HSC activation, hepatic steatosis, inflammation, and fibrosis in an HFHC-induced NASH model. The superior therapeutic effect of siIL11ra1@NP-AEAA is likely attributed to its potency in inhibiting IL-11-dependent ERK activation.

The biological safety of NPs was evaluated by biochemical parameters and pathological section analysis in HFHC-induced mice after the last administration. As shown in Figure S24, neither proposed siRNA therapeutics caused a pathological abnormality in the major organs (including heart, spleen, lung, and kidney) nor induced any significant changes in organ coefficient, blood urea nitrogen (BUN) or serum creatinine (CRE) compared with the healthy controls, suggesting negligible systemic toxicity within the treatment period.

**Inhibition of Paracrine IL-11-Induced HSC Activation by siIL11ra1@NP-AEAA.** Hepatocyte lipotoxicity is considered as an initiating pathophysiology of NASH, and it is associated with cytokine release. We hypothesized that secretion of cytokine from lipotoxic hepatocytes could activate HSCs through paracrine signaling. This mechanism could potentially explain the discrepancy between the therapeutic efficacy of siIL11@NP-AEAA and siIL11ra1@NP-AEAA treatments in two murine models of NASH. To evaluate our hypothesis, primary hepatocytes were isolated from normal chow-fed mice and loaded with palmitate to induce lipotoxicity. As shown in Figure 8A, a large amount of IL-11 was detected from supernatants of palmitate-treated hepatocytes (18-fold higher than the BSA control), indicating that hepatocytes secrete IL-11 in response to lipid overload. We then treated HSCs with conditioned medium derived from control or palmitate-loaded hepatocytes, as illustrated in Figure 8B. Immunofluorescence staining showed that medium from lipid-laden hepatocytes led to a noticeable increase in the expression of ACTA2 and COL1A1 in HSCs when treated with PBS or siScr@NP-AEAA (Figure 8C–E). NP-AEAA-mediated silencing of IL-11 in HSCs did not block ACTA2 and COL1A1 expression, while siIL11ra1@NP-AEAA treatment reversed the percentage of ACTA2$^+$ cells and COL1A1 immunofluorescence intensity to baseline levels (Figure 8C–F). These results reveal that NP-AEAA-formulated siRNA therapeutics targeting IL11ra1 can reverse HSC transformation and collagen deposition induced by paracrine IL-11 from lipotoxic hepatocytes, thus elucidating why siIL11ra1@NP-AEAA is more effective in two murine NASH models.

**DISCUSSION**

NASH is a form of progressive nonalcoholic fatty liver disease (NAFLD) that is characterized by hepatic lipid accumulation and inflammation. Approximately one-third of NASH patients will develop fibrosis. Severe fibrosis in NASH eventually leads to cirrhosis, liver failure, and hepatocellular carcinoma, and NASH is on track to become the leading cause of liver transplantation. Enormous effort has been invested to treat steatosis/hepatitis, but unfortunately there are currently no effective therapeutics approved for clinical use against NASH. Additionally, only very few approaches targeting fibrogenic pathways have been explored, especially after simtuzumab (an anti-LOXL2 monoclonal antibody) and selonsertib (a selective inhibitor of ASK1) failed in phase II and III trials, respectively.

Although the exact mechanisms underlying NASH pathogenesis are yet to be fully understood, it is widely accepted that HSC activation represents a key step in liver fibrosis since aHSCs are the major source of ECM components and profibrogenic cytokines. Recent studies have indicated that overexpression of IL-11 and IL11ra1 by aHSCs are closely associated with ERK-driven myofibroblast transformation and ECM production that are involved in NASH pathology.

These findings, combined with our immunohistochemistry and Western blotting results, bring to the forefront IL-11 and IL11ra1 as promising targets, and our developed aHSC-targeting NP-mediated silencing of the IL-11 signaling pathway may provide insights into the treatment of NASH and related hepatic fibrosis.

RNAi-based approaches leveraging the IL-11-mediated signaling pathway represent attractive options for combating fibrotic liver diseases, but the translational potential is limited by the lack of delivery platforms that enable the specific transfer of siRNA therapeutics to aHSCs. Efforts have been made to develop targeted siRNA delivery systems for the treatment of hepatic fibrosis. Examples include VA-coupled liposomes that target the RBP receptor, pPB peptide-modified lipid nanoparticles (LNPs) that recognize the platelet-derived growth factor receptor β (PDGFR-β) receptor, and polymer conjugates that target the CD44 receptor. However, most of these delivery systems lack specificity and have not been fully investigated in clinically relevant NASH models. To the best of our knowledge, NP-aided delivery of siRNA to aHSCs in the fibrotic NASH liver with high selectivity has been rarely reported. In this study, we constructed a lipid-polymer hybrid NP platform using our previously reported lipid-like compound G0-C14 and copolymer PLGA-PEG conjugates for delivery of siIL11 or siIL11ra1, which combines the benefits of both lipid and polymer systems to address barriers associated with siRNA delivery while overcoming some of their disadvantages. We further functionalyzed the NPs with aHSC-targeting moieties to specifically deliver siRNA therapeutics to aHSCs in the liver. Additionally, considering that HSCs are located within the Disse space adjacent to liver sinusoidal endothelial cells (LSECs) that limits access to larger NPs, we formulated siRNA-loaded NPs using a microfluidic approach to allow for precise tuning of NP properties, including particle size, PDI and stability. The resultant NPs have an average size of ~85 nm, the preferred size range that facilitates NP penetration across the fenestrations of LSECs (about 50–200 nm) and subsequent entry into the aHSCs.

Note that BMS-986263 (ND L02-s0201), a VA-coupled liposome containing siRNA against heat shock protein 47 (HSP47, a collagen-specific chaperone), is the only HSC-targeting nanoparticle tested in clinical trials. This targeting approach exploits the fact that HSCs take up and store VA via the RBP receptor. Intriguingly, the data reported here demonstrate that compared with VA-modified NP, more NP-AEAA accumulates within fibrotic livers and is primarily colocalized with Sig-1R. Our in vivo results reveal that Sig-1R is highly expressed by aHSCs in fibrotic NASH livers but barely detectable in healthy livers, indicating that NP-AEAA can specifically target aHSCs via the AEA-Sig-1R interaction.

We next evaluated the therapeutic potential of NP-AEAA incorporating siRNA against IL11 (siIL11@NP-AEAA) or IL11ra1 (siIL11ra1@NP-AEAA). Stimulation with various NASH factors (including TGF-β1, bFGF, PDGF, and H2O2) promotes HSC differentiation, migration, and invasion and ECM deposition, which are remarkably inhibited by both siIL11@NP-AEAA and siIL11ra1@NP-AEAA treatment. In
contrast, siIL11@NP-AEAA shows marginal effects on HSC activation and ECM production that are induced by stimulation with IL-11 secreted from lipotoxic hepatocytes whereas siIL11ra1@NP-AEAA exerts potent antifibrotic effects.

We investigated the in vivo therapeutic effects of siIL11@NP-AEAA and siIL11ra1@NP-AEAA in two well-established murine models of NASH induced by HFCMCD and HFHC diets. In the HFCMCD model, methionine- and choline-deficiency inhibits the production of very low-density lipoprotein (VLDL) that is required for triglyceride export from the liver, and thereby leads to rapid liver fat accumulation when combined with a high-fat diet. \cite{57,58}

This model mimics histopathological features of NASH with steatosis, liver cell death, inflammation, and fibrosis but notably is not related to the pathogenesis of human NASH due to nutritional deficiency. The data reported here reveals that siIL11ra1@NP-AEAA significantly reduces fibrosis and inflammation compared with siIL11@NP-AEAA and nontargeted siIL11ra1@NP, but does not improve steatosis in the HFCMCD model, most likely due to the fact that HFCMCD-induced steatosis is driven by artificial means. To gather additional data toward a more well-rounded picture of this disease, we included another mouse HFHC model in our study. In the HFHC model, a chronic high-fat and high-cholesterol diet feeding increases de novo lipogenesis flux and causes steatosis, which is similar to that observed in NASH patients. \cite{57,59}

Consistent with the results observed in the HFCMCD model, siIL11ra1@NP-AEAA treatment markedly suppressed HSC differentiation and reduced the production of proinflammatory and profibrotic factors in NASH livers of HFHC mice, leading to restoration of liver structure and function. Additionally, siIL11ra1@NP-AEAA treatment ameliorates liver steatosis, showing disease-modifying activity. The superior therapeutic effects of siIL11ra1@NP-AEAA in both murine models of NASH are attributed to the inhibition of paracrine IL-11/ERK signaling in HSCs, which could not be achieved by siIL11@NP-AEAA. Taken together, a targeted nanoparticulate siRNA therapeutic that blocks the IL-11/ERK pathway by down-regulating IL11ra expression in aHSCs is demonstrated to attenuate the development of NASH and related fibrosis in multiple murine models.

It is worth noting that this aHSC-targeting NP platform can be extended to the delivery of multiple RNA therapeutics (e.g., mRNA and microRNA) involved in different profibrotic pathways to provide synergistic benefits for fibrotic liver diseases. Considering that cancer-related fibrosis is characterized by excessive collagen production and ECM accumulation, this aHSC-targeting siRNA treatment ameliorates liver steatosis, with the results observed in the HFCMCD model, consistent with those described in the HFHC model, whereas siIL11ra1@NP-AEAA treatment markedly suppressed HSC activation and ECM production that are induced by stimulation with IL-11 secreted from lipotoxic hepatocytes. \cite{IL11ra1}

**CONCLUSIONS**

In conclusion, we present a robust NP platform that enables aHSC-targeting delivery of siRNA against the IL-11 signaling pathway and investigated its therapeutic effect in HFCMCD- and HFHC-induced murine models of NASH as a proof-of-concept. This work demonstrates the promising translational potential of siRNA-based therapy for NASH and other liver diseases including related hepatic fibroses and liver metastases.

**EXPERIMENTAL SECTION**

**Mouse Model Establishment.** Male C57BL/6j mice at the age of 7 weeks were purchased from the Beijing Vital River. All animal experiments were approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong University. All mice were housed at a temperature of 25 ± 2 °C under a 12:12 light/dark cycle with 40–60% humidity for 1 week before experiments and allowed free access to water and standard chow.

In the HFCMCD model, 8-week-old C57BL/6j mice received either an HFCMCD diet (methionine- and choline-deficient diet supplemented with 1% cholesterol and 46 kcal% fat; TP3622655, TrophicDiet) or normal chow (TP3622645C, TrophicDiet) ad libitum for a total of 12 weeks. In the HFHC model, 8-week-old C57BL/6j mice received either an HFHC diet (containing 40% fat and 2% cholesterol; TP2834040, TrophicDiet) or normal chow (TP2834020C1, TrophicDiet) ad libitum for a total of 22 weeks. In both NASH models, littermate mice fed with normal chow were used as healthy controls.

**Synthesis and Characterization of Cationic Lipid Compound G0-C14.** G0-C14 was synthesized by reacting poly-amidoamine (PAMAM) dendrimer generation 0 with 1,2-epoxytetradecane according to a previously described procedure. \cite{27}

In brief, PAMAM dendrimer G0 and 1,2-epoxytetradecane were mixed at a molar ratio of 1:6 and stirred at 90 °C for 2 d. The reaction mixture was purified by column chromatography on silica gel (CH2Cl2/MeOH/NH4OH = 75/22/3 v/v/v), yielding a final product with three fewer tails than the total possible for a designated amine monomer. 1H NMR (400 MHz, Chloroform-d): δ 4.57 (s, 8H), 3.67–2.25 (m, 51H), 1.62–0.96 (m, 106H), 0.87 (t, J = 6.6 Hz, 15H).

**Synthesis and Characterization of Targeting Polymeric Excipients.** PLGA-PET-VA. We first synthesized carboxyl-terminated PLGA-PET (PLGA-PET-COOH) by conjugating NH2-PET-COOH with PLGA according to our previously reported procedure. \cite{60}

Briefly, PLGA (5 μmol) and EDC-HCl (0.05 mmol) were dissolved in 1.5 mL of anhydrous DCM, and then 10 μL of NHS (0.05 mmol) dissolved in anhydrous DMSO was added to activate carboxyl groups. After the mixture was stirred at room temperature for 2 h, PLGA-NHS was obtained by precipitating in cold methanol/diethyl ether (50/50 v/v) and dried under vacuum. In the following reactions, PLGA-NHS and NH2-PET-COOH were dissolved in 2 mL of anhydrous DCM, and then 10 μL of DIPEA was added. The mixture was stirred at room temperature for 24 h. PLGA-PET-COOH was obtained by precipitation in cold methanol/diethyl ether (50/50 v/v), further washed three times, and dried under vacuum. The obtained PLGA-PET-COOH was reacted with the hydroxyl group of VA to yield VA-conjugated PLGA-PET (PLGA-PET-VA). In brief, PLGA-
PEG-COOH (5 μmol), vitamin A (10 μmol), DMAP (25 μmol), and EDC-HCl (25 μmol) were dissolved in 1.5 mL of anhydrous DCM and stirred in the dark at 60 °C for 24 h. PLGA-PEG-VA was obtained by purification in cold methanol/diethyl ether (50/50 v/v) three times and dried under a vacuum for further use. Yield: 90.2%. The 1H NMR spectrum of PLGA-PEG-COOH is shown in Figure S6. 

IL11-targeting siRNA (siIL11): 5′-GGG AAU CUU CUC UUG CCU UdTdT-3′ (sense strand) and 5′-AGC GCA AGA GUU CAC UdTdT-3′ (antisense strand); IL11ra1-targeting siRNA (siIL11ra1): 5′-GAG AUC UCU CUC UUG CCU UdTdT-3′ (sense strand) and 5′-AAG GCA AGA GAU UCC UdTdT-3′ (antisense strand); scrambled siRNA (scrIL1): 5′-UUC GCC GGU GCC AGC UdTdT-3′ (sense strand) and 5′-AGC UGA CAC GGU CGG ADdTT-3′ (antisense strand); FAM-labeled siRNA was synthesized by attaching the FAM dye to both the sense and antisense strands of scrambled siRNA.

**Physicochemical Characterization of siRNA-Loaded NPs.** The average particle diameter and zeta potential of various siRNA-loaded NPs were measured using a ZetaSizer dynamic light-scattering analyzer (Malvern, UK). Each sample was adjusted to a concentration of 0.1 mg/mL and equilibrated for 5 min at 25 °C before measurements were taken.

Encapsulation efficiency (EE) of siRNA was determined using the Quant-it Ribogreen kit (Invitrogen, USA). Briefly, siRNA-loaded NPs were incubated with 1X TE buffer in the presence or absence of 2% Triton X-100 and vortexed for 3 min. For the high-range calibration curve, a series of RNA standard solutions were prepared at designated concentrations. NP samples and RNA standards were mixed with a 200-fold dilution of the Ribogreen reagent for 5 min at room temperature. The fluorescence intensity was measured by the Multimode Fluorescence Microplate Reader (Ex/Em: 480/520 nm, Tecan, Switzerland). NP samples treated with 2% Triton X-100 represent the total siRNA content, while untreated samples represent the free siRNA content. The EE (%) was calculated from the following equation:

\[
EE\% = \frac{\text{total siRNA content} - \text{free siRNA content}}{\text{total siRNA content}} \times 100%
\]

For morphological observation, siRNA@NP and siRNA@NP-AEAA were dropped onto a copper grid (300 mesh) and air-dried following staining with 1% phosphotungstic acid for 2 min. After that, the air-dried samples were observed under TEM (Thermo Scientific, USA).

**In Vitro Stability.** To evaluate the serum stability of siRNA@NP-AEAA, 40 μL of siRNA@NP-AEAA (150 nM siRNA) was incubated with 10 μL of FBS in a 37 °C water bath and collected at predetermined time intervals (0, 3, 6, 12, and 24 h). Then, the obtained samples were mixed with 10 μL of EDTA (0.1 M) and heated at 85 °C for 10 min to inactivate RNase, followed by incubation with 8 μL of polyionan heparin (25 mg/mL) for 50 min at room temperature to dissociate siRNA from NPs. Subsequently, the samples underwent agarose gel electrophoresis for further analysis. Naked siRNA served as the negative control and was treated according to the same procedure.

To check the storage stability of siRNA@NP-AEAA, the freshly prepared NPs were dispersed in PBS solution (pH = 7.4) containing 20% FBS for 72 h in a 37 °C water bath. Changes in the particle size and PDI were recorded at predetermined intervals.

**Cell Culture.** The rat liver stellate cell line HSC-T6 (CL-0116) was purchased from Procell Life Science&Technology Co., Ltd. The NIH/3T3 cell line (G6M 6) derived from mouse embryonic fibroblasts was kindly provided by Cell Bank/ Stem Cell Bank, Chinese Academy of Sciences. Primary HSCs were isolated from male C57BL/6J mice by perfusion of the liver with Pronase and collagenase,62 followed by purification via Percoll (Yeasen, China) gradient centrifugation. qHSCs were serum-starved for 24 h and stimulated with TGF-β1 (20 ng/mL in a culture medium containing 1% FBS) for 48 h to transform into aHSCs. Primary hepatocytes were isolated from mouse livers using a modified in situ collagenase perfusion and low-speed centrifugation method.62 Freshly isolated hepatocytes were plated onto collagen I-coated 12-well plates at a density of 5 × 10² cells per well. All cells were cultured in DMEM.
medium containing 10% fetal bovine serum (FBS), 1% (v/v) penicillin, and 1% (v/v) streptomycin at 37 °C in the presence of 5% CO₂.

In Vitro Cytotoxicity and Cellular Uptake Analysis. HSC-T6, NIH/3T3, and primary mouse hepatocytes were seeded into 96-well plates at a density of 5 × 10⁴ cells per well and maintained for 24 h. Then, the cells were treated with siRNA@NP or siRNA@NP-AEA at different concentrations (from 10 to 500 μg/mL) in serum-free DMEM. After incubation for 24 h, 10 μL of CCK-8 was added to each well and further incubated for 1 h at 37 °C. Untreated cells were regarded as the positive control. The cell viability in each well was measured at a wavelength of 450 nm by the Multimode Fluorescence Microplate Reader (Tecan, Switzerland).

The fluorescently labeled NPs were incubated with qHSCs or aHSCs for 4 h at a siRNA concentration of 50 nM. For the competitive inhibition test, aHSCs were preincubated with excess Sig-1R antibody (30 μg/mL) for 2 h. Then, the cells were fixed in 4% paraformaldehyde, stained with DAPI (2 μg/mL), and observed by confocal microscopy (Leica, Germany). Flow cytometry (BD Biosciences, USA) was also utilized to analyze the intracellular fluorescence intensity of the collected cells.

Immunofluorescence Staining of HSCs. HSCs were seeded into 15 mm confocal dishes at a density of 3.0 × 10⁴ cells per dish and cultured at 37 °C overnight. HSCs were then starved in serum-free DMEM for 24 h and subsequently stimulated with TGF-β1 (20 ng/mL), bFGF (30 ng/mL), PDGF (40 ng/mL), or H₂O₂ (0.2 mM) in a DMEM culture medium containing 1% FBS for an additional 48 h. HSCs without any stimulation were used as the control group. The supernatant from HSCs was assessed using an IL-11 ELISA kit to determine the amount of secreted IL-11 according to the manufacturer’s protocol. For immunofluorescence staining, HSCs were fixed in 4% paraformaldehyde for 10 min, permeabilized in 0.1% Triton X-100 for 20 min, and incubated with 3% BSA for 1 h to block the nonspecific sites. After that, cells were incubated with rabbit anti-ACTA2 (1:600, Servicebio, China) or rabbit anti-COL1A1 (1:800, Servicebio, China) for 48 h at 4 °C, followed by incubation with Alexa Fluor 488-conjugated goat anti-rabbit secondary antibody (1:500, Servicebio, China) or rabbit anti-COL1A1 (1:300, Proteintech, China), Cy5-conjugated goat anti-rabbit secondary antibody (1:800, Servicebio, China), for 1 h at room temperature. After washing with PBS, cells were stained with DAPI and imaged using a confocal microscopy (Leica, Germany).

To study the efficacy of NP-AEA formulated siRNA therapeutics on HSC activation, HSCs were treated with PBS, siScr@NP-AEA, siLL11@NP-AEA, or siLL11@NP-AEA (50 nM siRNA) in serum-free DMEM for 4 h. Then, the culture medium was removed, and HSCs were further starved in serum-free DMEM for 24 h, followed by incubation with various NASH stimuli for an additional 48 h. HSCs treated with PBS and without any stimulation served as the negative control state. The fluorescence images of ACTA2 and COL1A1 in HSCs were observed by confocal microscopy (Leica, Germany).

Migration and Invasion Assay. HSCs were equally seeded onto the upper side of the polycarbonate membrane coated with (for invasion assay) or without (for migration assay) Matrigel. HSCs were then treated with PBS, siScr@NP-AEA, siLL11@NP-AEA, or siLL11@NP-AEA (50 nM siRNA) in serum-free DMEM for 4 h. Then, the culture medium was removed, and HSCs were further starved in serum-free DMEM for 24 h. Subsequently, DMEM containing TGF-β1 (20 ng/mL) and 1% PBS was added into the lower chamber to induce the migration or invasion of HSCs. After a 48-h stimulation, cotton swabs were used to gently remove cells failing in passing through the membrane. Cells that migrated or failing in passing through the membrane. Cells that migrated or invaded toward the lower chamber were fixed in 4% paraformaldehyde and stained with crystal violet for 10 min. After that, cells were washed by PBS thrice and observed using an optical microscope (Olympus, Japan) for quantification.

In Vivo and Ex Vivo Imaging. The biodistribution of different NP formulations in HFCMCD-induced fibrotic mice was determined by an in vivo imaging system (IVIS, PerkinElmer, USA). Briefly, HFCMCD mice were randomly divided into 3 groups and intravenously injected with siRNA@5-5-NP, siRNA@5-5-NP-Va, or siRNA@5-5-NP-AEA (0.6 mg/kg of siRNA), respectively. The mice were sacrificed, and heart, liver, spleen, lung, and kidneys were removed 24 h post administration. The fluorescence of each organ was assessed using an ex vivo imaging system that utilized the Cy5.5 channel across groups. To further determine the target specificity of siRNA@NP-AEA, normal chow-fed healthy mice were injected with siRNA@5-5-NP or siRNA@5-5-NP-AEA (0.6 mg/kg of siRNA) via tail vein. After 24 h, the mice were sacrificed, and the major organs were excised for ex vivo imaging.

Immunofluorescence Analysis. To investigate cellular localization of different NPs, the collected liver tissues were fixed in neutral paraformaldehyde fixative for 24 h, dehydrated in 15% and 30% sucrose solution overnight at 4 °C, and subsequently snap frozen in the O.C.T. compound (ServoBio). Frozen liver tissues were cut into 8 μm sections and blocked with 3% BSA for 30 min at room temperature, followed by incubation with primary antibodies at 4 °C overnight. After washing with PBS three times, sections were incubated with fluorescent secondary antibodies for 50 min at room temperature, counterstained with DAPI for 5 min, then covered with a coverslip, and imaged with confocal microscopy (Leica, Germany) at the designated signal wavelength. In order to study the expression and colocalization of Sig-1R, liver sections derived from healthy control mice and untreated HFCMCD mice were performed with immunofluorescence analysis according to the procedures described above. Antibodies used for immunofluorescence were listed as follows: rabbit anti-ACTA2 (1:600, Servicebio, China), mouse anti-Sig-1R (1:200, Santa Cruz, USA), CoraLite594-conjugated goat anti-rabbit secondary antibody (1:300, Proteintech, China), CoraLite594-conjugated goat anti-mouse secondary antibody (1:300, Proteintech, China), Cy5-conjugated goat anti-rabbit secondary antibody (1:800, Servicebio, China).

In Vivo Efficacy Evaluation in NASH Models. Mice receiving either HFCMCD or HFFHC diet were intravenously injected with 0.15 mL of saline, siScr@NP-AEA, siLL11@NP-AEA, or siLL11@NP-AEA (50 nM siRNA) in a siRNA dose of 0.6 mg/kg) twice weekly for a period of 4 weeks, following the administration schedule shown in Figure 5A and Figure 6A, respectively. All mice were sacrificed 3 days after the final injection. Blood and the main organs (heart, liver, spleen, lung, and kidney) were collected for further analysis.

Histological Analysis. For histological analysis, livers and other major tissues were fixed in neutral paraformaldehyde fixative for 48 h and embedded in paraffin and then cut into 5 μm slices, dewaxed in xylene, and hydrated with graded ethanol. Tissue slices (including heart, liver, spleen, lung, and kidney) were analyzed with hematoxylin and eosin (H&E) staining. To detect the collagen deposition in livers, liver sections were processed with Masson’s trichrome staining and Sirius red staining with standard protocols. For immunohistochemistry analysis, paraffin-embedded liver sections were first treated with the corresponding primary antibodies and subsequently incubated with HRP-conjugated secondary antibodies. After washing three times, the sections were developed with 3,3′-diaminobenzidine (DAB) (brown) and counterstained with hematoxylin for clear visualization of nuclei (blue). Liver tissues embedded in O.C.T. were cut into 8 μm sections and used for Oil red O staining. The percentage of the stained fibrotic area (the blue area indicated in Masson’s trichrome staining and the red area indicated in Sirius red staining), IL-11- and ACTA2-positive area, and Oil red O-positive area in each sample were calculated using the NIH Image[] software (Bethesda, USA). Images were taken with an optical microscope (Olympus, Japan).

Colorimetric Assays. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (CRE) levels were measured using commercially available kits according to the manufacturer’s standards (Nanjing Jiancheng Bioengineering Institute, China). Total lipids were extracted from liver samples using the Folch method as previously reported, and the levels of liver triglyceride were quantified using Triglyceride Assay Kit (Nanjing Jiancheng Bioengineering Institute, China). Hydroxyproline content in liver tissues was measured using a Hydroxyproline Assay Kit following the manufacturer’s instructions (Nanjing Jiancheng Bioengineering Institute, China).
Quantitative Reverse Transcription PCR (qRT-PCR) Analysis. Total RNA was isolated from the liver tissues using the RNA extraction reagent (Vazyme) and reverse transcribed into cDNA with a HiScript Q RT SuperMix Kit (Vazyme). Expression of Acta2, Colla1, Ccl2, Ccl5, Timp1, and Mmp2 was measured using ChamQ Universal SYBR qPCR Master Mix (Vazyme) on StepOnePlus Real-Time PCR System (Applied Biosystems, USA). All of the primer sequences are listed in Supplementary Table 2. The relative expression of target mRNA was analyzed by the 2\(^{-\Delta\Delta Ct}\) method, and GAPDH was used as the internal reference.

Western Blotting. Total protein samples were extracted from HSCs or mouse livers with a RIPA lysis buffer (Beyotime) containing phosphatase and protease inhibitors (Epizyme). The protein concentration was determined using the BCA Protein Assay Kit (Share-bio). Protein samples were separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to poly(vinylidene difluoride) membranes (Millipore). The membranes were blocked with a TBST buffer containing 5% skim milk for 30 min at room temperature and then incubated with primary antibodies overnight at 4 °C. Membranes were washed and incubated with conjugated secondary antibodies for 1 h and visualized using Omnifluor enhanced chemiluminescence (Epizyme). GAPDH was used as a loading control to normalize the levels of protein. Antibodies were rabbit anti-IL-11 (1:1000, Proteintech, China) and anti-IL11RA (1:1000, Proteintech, China), mouse anti-GAPDH (1:5000, ABclonal, China), rabbit anti-ACTA2 (1:1000, Servicebio, China) and anti-COL1A1 (1:1000, Servicebio, China), mouse anti-ERK 1/2 (1:100, Santa Cruz, USA) and anti-p-ERK 1/2 (1:100, Santa Cruz, USA), HRP-conjugated goat anti-mouse IgG (1:5000, Proteintech, China), and HRP-conjugated goat anti-rabbit IgG (1:5000, Signalway Antibody, USA).

Palmitate Treatment in Vitro. Primary mouse hepatocytes were starved in serum-free DMEM for 12 h and then treated with BSA-conjugated palmitate (0.5 mM) for 48 h to induce lipotoxicity. Hepatocytes treated with fatty-acid-free BSA were used as the negative control. Secreted IL-11 from hepatocytes was quantified using an ELISA kit according to the manufacturer’s protocol.

Inhibition Assay of Paracrine-Induced HSC Activation. To determine whether NP-AEEA formulated siRNA therapeutics could inhibit HSC activation induced by paracrine IL-11, HSCs were treated with PBS, siScr@NP-AEEA, siIL11@NP-AEEA, or siIL11ra1@NP-AEEA (50 nM siRNA) for 4 h, and starved in serum-free DMEM for 20 h. Then, HSCs were incubated with conditioned medium from BSA or palmitate-treated hepatocytes for 48 h. The fluorescence images of ACTA2 and COL1A1 expressed by HSCs were observed by confocal microscopy (Leica, Germany) and analyzed using the NIH ImageJ software (Bethesda, USA).

Statistical Analysis. All statistical data are analyzed using GraphPad Prism 8.2.1 software. Results are presented as the mean ± standard deviation (SD). The two-tailed unpaired Student’s t test was used to determine statistical significance when only two groups were compared. For comparisons between multiple groups, one-way analysis of variance (ANOVA) with a post hoc Tukey test (when several groups were compared to each other) or Dunnett’s test (when several groups were compared to one group) was used. Statistical significance was displayed as follows: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/10.1021/acsnano.3c03217.

Immunohistochemistry staining; synthesis route and characterization of materials; cellular uptake analysis; histopathological analysis; in vivo biodistribution evaluation; immunofluorescent staining and subcellular localization analysis; ELISA assay; immunofluorescence staining; quantitative analysis of Western blots; assessment of antifibrotic effect; Western blotting analysis; histopathological analysis; in vivo safety evaluation; characterization of NP formulations; primer sequences (PDF)

AUTHOR INFORMATION

Corresponding Authors

Xiaoyang Xu — Department of Chemical and Materials Engineering and Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, New Jersey 07102, United States; orcid.org/0000-0002-1634-3329; Email: xiaoyang.xu@njit.edu

Xue-Qing Zhang — Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmacy, National Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, Shanghai 200240, P. R. China; orcid.org/0000-0002-4954-2586; Email: xueqingzhang@sjtu.edu.cn

Authors

Chenshuang Zhang — Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmacy, National Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, Shanghai 200240, P. R. China

Yilong Teng — Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmacy, National Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, Shanghai 200240, P. R. China

Fengqiao Li — Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, New Jersey 07102, United States

William Ho — Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, New Jersey 07102, United States

Xin Bai — Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmacy, National Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, Shanghai 200240, P. R. China

Complete contact information is available at: https://pubs.acs.org/10.1021/acsnano.3c03217

Author Contributions

X.-Q.Z., X.X., C.Z., and W.H. reviewed and edited the paper. X.-Q.Z., Xin Bai, and William Ho contributed to the concept, design, and data analysis. C.Z. and X.-Q.Z. wrote the paper. X.-Q.Z. orcid.org/0000-0002-4954-2586; X.-Q.Z. orcid.org/0000-0002-1634-3329; X.-Q.Z. orcid.org/0000-0002-0876-373X; Xin Bai orcid.org/0000-0002-4954-2586; William Ho orcid.org/0000-0002-1634-3329; and W.H. reviewed and edited the paper.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the “Open Competition to Select the Best Candidates” Key Technology Program for Nucleic Acid Drugs of NCTIB (Grant No. NCTIB2022HS02002), the Natural Science Foundation of Shanghai (23ZR1427600), Shanghai Jiao Tong University Scientific and Technological Innovation Funds (19X160020005, Grant No. 2019TPA10), Foundation of National Facility for Translational Medicine (Shanghai) (TMSK-2020-008), the Interdisciplinary Program
Hepatology 2022

BMS-986263 in patients with advanced hepatic fibrosis: 36-week activities.

treat hepatic cirrhosis by dual antifibrotic and anti-inflammatory activities.

Hepatology 2020, 63, 301–3073.

Chimeric Peptide Engineered Bioregulator for Metastatic Tumor Immunotherapy through Macrophage Polarization and Phagocytosis Restoration

Aged-Signal-Eliciting Nanoparticles Stimulated Macrophage-Mediated Programmed Removal of Inflammatory Neutrophils


(59) Lambert, J. E.; Ramos-Roman, M. A.; Browning, J. D.; Parks, E. J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014, 146 (3), 726–735.


